Basics uniQure N.V. Ordinary Shares uniQure NV is engaged in the field of gene therapy platform across three therapeutic focus areas: Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. IPO Date: March 1, 2014 Sector: Healthcare Industry: Biotech Market Cap: $764.29M Activated in VL: True Average Daily Range Avg Daily Range: $0.64 | 2.91% Avg Daily Range (30 D): $0.30 | 2.04% Avg Daily Range (90 D): $0.48 | 3.65% Institutional Daily Volume Avg Daily Volume: .53M Avg Daily Volume (30 D): .95M Avg Daily Volume (90 D): 1.4M Trade Size Avg Trade Size (Sh.): 93 Avg Trade Size (Sh.) (30 D): 71 Avg Trade Size (Sh.) (90 D): 79 Institutional Trades Total Inst.Trades: 2,466 Avg Inst. Trade: $1.6M Avg Inst. Trade (30 D): $1.96M Avg Inst. Trade (90 D): $1.61M Avg Inst. Trade Volume: .08M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.82M Avg Closing Trade (30 D): $2.62M Avg Closing Trade (90 D): $2.19M Avg Closing Volume: 94.25K     News Jun 11, 2025 @ 12:00 PM uniQure Announces Appointment of Kylie O’Ke... Source: N/A Feb 7, 2025 @ 2:12 PM CSL Behring's Gene Therapy HEMGENIX® (etranacog... Source: Prnewswire Jan 7, 2025 @ 9:49 PM uniQure Announces Proposed Public Offering Source: N/A Aug 30, 2024 @ 12:59 PM Gene Therapy Market Size to Reach USD 54.39 Billio... Source: Sns Insider Jul 10, 2024 @ 12:01 PM Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.... Source: Avi Kapoor Financials   TTM Q1 2025 Q3 2024 Basic EPS $-.82 $-.91 Diluted EPS $-.82 $-.91 Revenue $ $ 1.57M $ 2.29M Gross Profit $ $ 1.37M $ 2.02M Net Income / Loss $ $ -43.64M $ -44.38M Operating Income / Loss $ $ -39.33M $ -40.23M Cost of Revenue $ $ .2M $ .26M Net Cash Flow $ $ 58.33M $ -37.96M PE Ratio